Tigermed and Sinopharm-CICC contributed to a round that will support clinical testing for Hinova's pipeline of cancer and metabolic disease candidates.
China-based cancer and metabolic disease drug developer Hinova Pharmaceuticals has completed a RMB1bn ($147m) series C round that included clinical research organisation Tigermed, DealStreetAsia reported today.
Sinopharm-CICC, a private equity fund formed by pharmaceutical company Sinopharm and fund manager CICC Capital, also took part, as did CCB International, an affiliate of financial services firm China Construction Bank, and Sealand Innovation, part of brokerage firm Sealand Securities.
The round was filled out by Founder Securities subsidiary Founder H Fund, municipal-owned investment…
